阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎患者临床疗效观察  

Clinical effect of adefovir dipivoxil combined with compound Bijia Ruangan tablets in treatment of patients with chronic hepatitis B

作　　者：朱琼香 李小丹 

机构地区：[1]湖北省恩施州中心医院,445000

出　　处：《实用肝脏病杂志》2015年第3期258-261,共4页Journal of Practical Hepatology

摘　　要：目的探讨阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎患者的临床疗效。方法将80例慢性乙型肝炎患者随机分为对照组和治疗组,40例对照组采用阿德福韦酯治疗,40例治疗组在对照组治疗的基础上加用复方鳖甲软肝片治疗。两组患者均治疗6个月,观察患者的临床症状和体征、肝功能指标、肝纤维化指标、B超影像学检查指标(门静脉内径、脾静脉内径、脾脏厚度)、HBV DNA载量、HBe Ag阴转以及HBe Ag血清学转换。结果在治疗结束时,对照组患者ALT、AST、ALB、TBIL分别为(57.84±16.11)U/L、(51.55±18.46)U/L、(36.21±4.69)g/L、(25.74±4.85)μmol/L,治疗组患者分别为(38.47±13.43)U/L、(35.74±15.17)U/L、(42.64±4.52)g/L、(15.27±3.36)μmol/L;对照组患者HA、LN、PC-Ⅲ、Ⅳ-C分别为(168.53±86.21)g/L、(121.45±38.56)g/L、(131.61±34.49)g/L、(123.53±31.67)g/L,治疗组患者分别为(87.57±42.53)g/L、(62.74±21.87)g/L、(88.74±28.32)g/L、(67.63±16.67)g/L;对照组患者门静脉内径、脾静脉内径、脾脏厚度分别为(1.42±0.20)cm、(0.78±0.09)cm和(4.65±0.43)cm,治疗组患者分别为(1.31±0.21)cm、(0.74±0.07)cm和(4.24±0.38)cm。治疗组上述指标均较对照组改善明显(P<0.05);对照组患者HBV DNA载量从治疗前(6.12±1.66)log10 copies/ml下降至(3.57±1.21)log10 copies/ml,治疗组患者从治疗前(5.93±1.84)log10 copies/ml下降至(3.43±1.17)log10 copies/ml,两组治疗后HBV DNA载量比较差异无统计学意义(P<0.05)。结论阿德福韦酯联合复方鳖甲软肝片治疗慢性乙型肝炎患者临床疗效好。Objective To investigate the clinical effect of adefovir dipivoxil（ADV） combined with Compound Biejia Ruangan tablets in the treatment of patients with chronic hepatitis B（CHB）. Methods 80 patients with CHB were randomly divided into control（n=40） and treatment group（n=40）. Patients in control group were given ADV,while patients in treatment group were given ADV combined with Compound Biejia Ruangan tablets for 6months. Clinical symptoms and signs,liver function,hepatic fibrosis indicators,abdominal ultrasonographic indicators such as portal vein diameter,splenic vein diameter as well as thickness of spleen,and serum HBV DNA levels,HBe Ag seroconversion after the treatment were recorded. Results At the end of the treatment,ALT,AST,ALB and TBil in patients of control group were（57.84±16.11） U/L,（51.55±18.46） U/L,（33.43±4.76） g/L and（25.74±4.85）μmol/L respectively,and those in patients of treatment group were（38.47±13.43） U/L,（35.74±15.17） U/L,（26.25±4.57） g/L and（15.27±3.36） μmol/L respectively;The HA,LN,PC-Ⅲ and Ⅳ-C in patients of control group were（168.53±86.21） μg/L,（121.45±38.56） μg/L,（131.61±34.49） μg/L and（123.53±31.67） μg/L respectively,and those in patients of treatment group were（87.57±42.53） μg/L,（62.74±21.87） μg/L,（88.74±28.32） μg/L and（67.63±16.67） μg/L respectively;The portal vein diameters,splenic vein diameters and thickness of spleen in patients of control group were（1.42±0.20） cm,（0.78±0.09） cm and（4.65±0.43） cm respectively,and those in patients of treatment group were（1.31±0.21）cm,（0.74±0.07） cm and（4.24±0.38） cm respectively;Above-mentioned indicators in treatment group had more remarkable decreased compared with patients in control group（P〈0.05）;The levels of serum HBV DNA after the treatment in patients of control group decreased from（6.12 ±1.66） log10 copies/ml to（3.57 ±1.21） log10copies/ml,and in patients of treatment group decreased fro

关 键 词：慢性乙型肝炎 阿德福韦酯 复方鳖甲软肝片 肝纤维化 

分 类 号：R512.62[医药卫生—内科学]